Early use of higher-efficacy therapies is recommended for patients with moderately to severely active Crohn disease (CD), ...

The American Gastroenterological Association (AGA) has released a comprehensively updated clinical guideline on the ...

In the video, Dr. Nicola J. Gullick, a Consultant Rheumatologist in Coventry and one of the investigators on the PRO-SPIRIT ...

The American Gastroenterological Association has released updated guidelines for treating moderate-to-severe Crohn’s disease, outlining 16 evidence-based recommendations that prioritize advanced ...

Samsung Bioepis Co., Ltd. has signed a settlement and license agreement with Johnson Johnson concerning the commercialization of PYZCHIVA, a biosimilar to Stelara (ustekinumab)1, in Europe. The terms ...

Both etanercept and ustekinumab have been shown to be strikingly effective in patients with psoriasis. A phase III trial comparing these two biologic agents for the treatment of moderate-to-severe ...

Unequal global access to inflammatory bowel disease (IBD) therapies creates profound health inequities. The increasing prevalence of IBD in Western countries, driven by high incidence rates and low ...

Interleukin-23 (IL-23) plays a pivotal role in the complex pathogenesis of both ulcerative colitis and Crohn's disease, making it a promising therapeutic target.1 Mirikizumab is a humanised IgG4 ...

Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless ...

Treatment of moderate-to-severe Crohn's disease should prioritize early use of higher-efficacy advanced therapies rather than step-up approaches, according to a new living clinical practice guideline ...

Bengaluru: Biocon has announced that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received approval ...